R&D News | pharmaphorum

News

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S

News

MSD gives warning to UK ahead of $1.3bn facility work

In 2017, MSD made the decision to open a $1.32 billion, 220,000 sq ft research facility in the heart of London’s ‘knowledge quarter’ around King’s Cross.

News

Santhera closes on first approval for DMD drug vamorolone

Swiss biotech Santhera is on the brink of its first regulatory approval for Duchenne muscular dystrophy treatment vamorolone, after getting a positive opinion on the drug

News

Lilly to file mirikizumab in Crohn’s after FDA colitis snub

Eli Lilly has said it plans to file its anti-IL-23p19 antibody mirikizumab for approval as a treatment for Crohn’s disease next year after it hit all its targets in a phas

News

Pilot study finds VR training benefit in depression

People with depression can sometimes have impaired memory, particularly for positive events, which can contribute to cognitive problems and impair their daily lives.

News

Agomab raises $100m for Crohn’s drug, and other financings

Agomab Therapeutics has closed a $100 million third-round financing, heading a list of recent funding rounds that also features AstronauTx, MinervaX, Precede Bio and Limma

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

MSD gives warning to UK ahead of $1.3bn facility work

Santhera closes on first approval for DMD drug vamorolone

Lilly to file mirikizumab in Crohn’s after FDA colitis snub

Pilot study finds VR training benefit in depression

Agomab raises $100m for Crohn’s drug, and other financings

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks